Crescita Therapeutics, Inc. (CTX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Crescita Therapeutics, Inc.

Æterna Zentaris, Inc.

Medicure, Inc.

Valeo Pharma, Inc.

Resverlogix Corp.

Revive Therapeutics Ltd.

PreveCeutical Medical, Inc.

PharmaTher Holdings Ltd.

Avricore Health, Inc.

Core One Labs, Inc.

XORTX Therapeutics, Inc.

Why is Crescita Therapeutics, Inc. ?

With a growth in Net Sales of 52.47%, the company declared Very Positive results in Jun 25

OPERATING CASH FLOW(Y) Highest at CAD 1.29 MM
RAW MATERIAL COST(Y) Fallen by -18.3% (YoY)
DEBTORS TURNOVER RATIO(HY) Highest at 8.87%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -22.13%, its profits have risen by 52.4%

Below par performance in long term as well as near term

Along with generating -22.13% returns in the last 1 year, the stock has also underperformed S&P/TSX 60 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Crescita Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Crescita Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Crescita Therapeutics, Inc.

38.18%

0.31

46.99%

S&P/TSX 60

30.34%

1.54

14.62%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

5.77%

EBIT Growth (5y)

-188.25%

EBIT to Interest (avg)

-0.90

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.54

Sales to Capital Employed (avg)

1.11

Tax Ratio

0.46%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.23%

ROE (avg)

2.50%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.86

EV to EBIT

-6.14

EV to EBITDA

6.14

EV to Capital Employed

0.73

EV to Sales

0.28

PEG Ratio

0.10

Dividend Yield

ROCE (Latest)

-10.78%

ROE (Latest)

6.13%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

29What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CAD 2.04 MM

ROCE(HY)

Highest at 2.83%

RAW MATERIAL COST(Y)

Fallen by 0.51% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 2.11 times

DEBTORS TURNOVER RATIO(HY)

Highest at 13.86 times

NET SALES(Q)

At CAD 5.39 MM has Grown at 50.06%

PRE-TAX PROFIT(Q)

Highest at CAD 1.4 MM

NET PROFIT(Q)

Highest at CAD 1.38 MM

-1What is not working for the Company

CASH AND EQV(HY)

Lowest at CAD 16.49 MM

Here's what is working for Crescita Therapeutics, Inc.

Pre-Tax Profit

At CAD 1.4 MM has Grown at 234.13%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CAD MM)

Net Profit

At CAD 1.38 MM has Grown at 233.49%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CAD MM)

Operating Cash Flow

Highest at CAD 2.04 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CAD MM)

Net Sales

At CAD 5.39 MM has Grown at 50.06%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CAD MM)

Pre-Tax Profit

Highest at CAD 1.4 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CAD MM)

Net Profit

Highest at CAD 1.38 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CAD MM)

Inventory Turnover Ratio

Highest at 2.11 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 13.86 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by 0.51% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Crescita Therapeutics, Inc.

Cash and Eqv

Lowest at CAD 16.49 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents